Cargando…
Vaccines and Therapeutics Against Hantaviruses
Hantaviruses (HVs) are rodent-transmitted viruses that can cause hantavirus cardiopulmonary syndrome (HCPS) in the Americas and hemorrhagic fever with renal syndrome (HFRS) in Eurasia. Together, these viruses have annually caused approximately 200,000 human infections worldwide in recent years, with...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7002362/ https://www.ncbi.nlm.nih.gov/pubmed/32082263 http://dx.doi.org/10.3389/fmicb.2019.02989 |
_version_ | 1783494362695467008 |
---|---|
author | Liu, Rongrong Ma, Hongwei Shu, Jiayi Zhang, Qiang Han, Mingwei Liu, Ziyu Jin, Xia Zhang, Fanglin Wu, Xingan |
author_facet | Liu, Rongrong Ma, Hongwei Shu, Jiayi Zhang, Qiang Han, Mingwei Liu, Ziyu Jin, Xia Zhang, Fanglin Wu, Xingan |
author_sort | Liu, Rongrong |
collection | PubMed |
description | Hantaviruses (HVs) are rodent-transmitted viruses that can cause hantavirus cardiopulmonary syndrome (HCPS) in the Americas and hemorrhagic fever with renal syndrome (HFRS) in Eurasia. Together, these viruses have annually caused approximately 200,000 human infections worldwide in recent years, with a case fatality rate of 5–15% for HFRS and up to 40% for HCPS. There is currently no effective treatment available for either HFRS or HCPS. Only whole virus inactivated vaccines against HTNV or SEOV are licensed for use in the Republic of Korea and China, but the protective efficacies of these vaccines are uncertain. To a large extent, the immune correlates of protection against hantavirus are not known. In this review, we summarized the epidemiology, virology, and pathogenesis of four HFRS-causing viruses, HTNV, SEOV, PUUV, and DOBV, and two HCPS-causing viruses, ANDV and SNV, and then discussed the existing knowledge on vaccines and therapeutics against these diseases. We think that this information will shed light on the rational development of new vaccines and treatments. |
format | Online Article Text |
id | pubmed-7002362 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-70023622020-02-20 Vaccines and Therapeutics Against Hantaviruses Liu, Rongrong Ma, Hongwei Shu, Jiayi Zhang, Qiang Han, Mingwei Liu, Ziyu Jin, Xia Zhang, Fanglin Wu, Xingan Front Microbiol Microbiology Hantaviruses (HVs) are rodent-transmitted viruses that can cause hantavirus cardiopulmonary syndrome (HCPS) in the Americas and hemorrhagic fever with renal syndrome (HFRS) in Eurasia. Together, these viruses have annually caused approximately 200,000 human infections worldwide in recent years, with a case fatality rate of 5–15% for HFRS and up to 40% for HCPS. There is currently no effective treatment available for either HFRS or HCPS. Only whole virus inactivated vaccines against HTNV or SEOV are licensed for use in the Republic of Korea and China, but the protective efficacies of these vaccines are uncertain. To a large extent, the immune correlates of protection against hantavirus are not known. In this review, we summarized the epidemiology, virology, and pathogenesis of four HFRS-causing viruses, HTNV, SEOV, PUUV, and DOBV, and two HCPS-causing viruses, ANDV and SNV, and then discussed the existing knowledge on vaccines and therapeutics against these diseases. We think that this information will shed light on the rational development of new vaccines and treatments. Frontiers Media S.A. 2020-01-30 /pmc/articles/PMC7002362/ /pubmed/32082263 http://dx.doi.org/10.3389/fmicb.2019.02989 Text en Copyright © 2020 Liu, Ma, Shu, Zhang, Han, Liu, Jin, Zhang and Wu. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Microbiology Liu, Rongrong Ma, Hongwei Shu, Jiayi Zhang, Qiang Han, Mingwei Liu, Ziyu Jin, Xia Zhang, Fanglin Wu, Xingan Vaccines and Therapeutics Against Hantaviruses |
title | Vaccines and Therapeutics Against Hantaviruses |
title_full | Vaccines and Therapeutics Against Hantaviruses |
title_fullStr | Vaccines and Therapeutics Against Hantaviruses |
title_full_unstemmed | Vaccines and Therapeutics Against Hantaviruses |
title_short | Vaccines and Therapeutics Against Hantaviruses |
title_sort | vaccines and therapeutics against hantaviruses |
topic | Microbiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7002362/ https://www.ncbi.nlm.nih.gov/pubmed/32082263 http://dx.doi.org/10.3389/fmicb.2019.02989 |
work_keys_str_mv | AT liurongrong vaccinesandtherapeuticsagainsthantaviruses AT mahongwei vaccinesandtherapeuticsagainsthantaviruses AT shujiayi vaccinesandtherapeuticsagainsthantaviruses AT zhangqiang vaccinesandtherapeuticsagainsthantaviruses AT hanmingwei vaccinesandtherapeuticsagainsthantaviruses AT liuziyu vaccinesandtherapeuticsagainsthantaviruses AT jinxia vaccinesandtherapeuticsagainsthantaviruses AT zhangfanglin vaccinesandtherapeuticsagainsthantaviruses AT wuxingan vaccinesandtherapeuticsagainsthantaviruses |